A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

Trial Profile

A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs Ertugliflozin (Primary) ; Glimepiride; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms VERTIS SU
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 20 Mar 2018 Results of pooled analysis assessing the risk of UTIs, including complicated UTIs, in adult patients with T2DM receiving ertugliflozin relative to placebo or active comparators from 7 trials (NCT [VERTIS name]: 01958671 [MONO], 02036515 [SITA2], 02033889 [MET], 01986855 [RENAL], 01999218 [SU], 02099110 [FACTORIAL], 02226003 [SITA]) presented at The 100th Annual Meeting of the Endocrine Society
    • 01 Feb 2018 Results of Phase A published in the Diabetes Therapy
    • 08 Dec 2017 Results (n=4395) from the six VERTIS studies, presented at the 2017 Congress of the International Diabetes Federation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top